- Biotech company is focused on becoming a worldwide leader in R&D and sale of hemp-derived, CBD-based nutraceuticals, pharmaceuticals and dietary supplements
- ETST is developing three new CBD formulas in Canada under a provisory patent; it is also clinical testing its Hygee medical device for detecting sexually transmitted diseases in women
- With its Form 10 Registration Statement filing now effective, ETST will begin reporting annual, quarterly and periodic financial statements
Earth Science Tech, Inc. (OTCQB: ETST) anticipates that its uplisting to the OTCQB Venture Market will enable it to reach global recognition and increase liquidity as a leader in the hemp-based CBD space in several fields, such as cannabinoid products. It also develops innovative medical devices designed for multi-national marketing (http://cnw.fm/aUZj5).
The Florida-based company seeks to raise its recognition level and perform more R&D for the CBD industry. ETST manufactures, markets and distributes its own cannabinoid products, including capsules and oils. It is a leader in the medical cannabis markets, with its products available at retail health food stores and e-liquid smoke shops.
“Historically, up-listing to the OTCQB and being fully reporting has resulted in greater liquidity and awareness,” Nickolas S. Tabraue, president, director and chairman of ETST, stated in a news release (http://cnw.fm/Z2OIr). “We are committed to the higher level of corporate and financial disclosures required as an OTCQB fully reporting company, demonstrating our commitment to our loyal shareholders.”
In Canada, it is testing three new CBD IP formulations. It is also clinical testing its Hygee MSN-2 medical device for detection of sexually transmitted infections (STIs) in women at Québec’s Clinique Santé Amitié (http://cnw.fm/p0L4I).
It is developing two new products in Brazil in a joint venture with Bionatus Laboratrio Botnico of Brazil and its Canadian division Bionatus Botanical Laboratories, Inc. In the U.S., it is conducting studies with the University of Central Oklahoma on the impact of high grade full spectrum CBD on immune cells and breast cancer (http://cnw.fm/Ti0j6).
ETST holds several wholly owned subsidiaries. Cannabis Therapeutics is an emerging biotechnology company. KannaBidioiD manufactures and distributes in the recreational sector. Earth Science Foundation, Inc. is becoming a non-profit and accepts grants and donations to conduct additional studies. Earth Science Pharmaceutical develops medical diagnostic tools and vaccines. It also formed subsidiary Canno Inno Laboratories Inc., a strategic Montreal, Canada-based company that provides ETST with access to government grants.
For more information, visit the company’s website at www.EarthScienceTech.com
More from CannabisNewsWire
About CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.cannabisnewswire.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer
CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com
